Leerink Partnrs Has Positive View of Medpace FY2025 Earnings

Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) - Stock analysts at Leerink Partnrs lifted their FY2025 earnings estimates for shares of Medpace in a research report issued to clients and investors on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings per share of $12.66 for the year, up from their prior estimate of $12.46. Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Medpace's current full-year earnings is $12.29 per share. Leerink Partnrs also issued estimates for Medpace's FY2026 earnings at $13.07 EPS and FY2027 earnings at $14.27 EPS.

Other research analysts have also issued reports about the stock. William Blair reissued a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $370.00 to $328.00 in a report on Monday, April 14th. Leerink Partners started coverage on shares of Medpace in a report on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective for the company. Truist Financial decreased their price objective on shares of Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a report on Wednesday, April 23rd. Finally, Mizuho decreased their price objective on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a report on Wednesday, April 9th. Twelve research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $344.82.

Medpace Trading Down 1.4%

MEDP stock traded down $4.74 during mid-day trading on Wednesday, hitting $323.50. 293,644 shares of the company were exchanged, compared to its average volume of 377,752. The company has a market capitalization of $9.30 billion, a PE ratio of 24.69, a price-to-earnings-growth ratio of 5.94 and a beta of 1.47. Medpace has a twelve month low of $250.05 and a twelve month high of $459.77. The firm has a fifty day simple moving average of $305.61 and a 200 day simple moving average of $318.86.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. The business had revenue of $558.57 million during the quarter, compared to analyst estimates of $528.38 million. Medpace had a net margin of 19.31% and a return on equity of 54.36%. During the same period last year, the business earned $3.20 EPS.

Institutional Trading of Medpace

Several hedge funds have recently bought and sold shares of MEDP. Mawer Investment Management Ltd. bought a new stake in Medpace in the 1st quarter valued at about $212,131,000. Invesco Ltd. lifted its position in Medpace by 91.8% in the 4th quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock valued at $360,387,000 after purchasing an additional 519,186 shares during the last quarter. Vulcan Value Partners LLC lifted its position in Medpace by 221.6% in the 1st quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company's stock valued at $99,159,000 after purchasing an additional 224,578 shares during the last quarter. Norges Bank bought a new stake in Medpace in the 4th quarter valued at about $69,859,000. Finally, Fundsmith LLP bought a new stake in Medpace in the 4th quarter valued at about $42,372,000. 77.98% of the stock is currently owned by institutional investors.

Insider Activity at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the transaction, the director directly owned 2,998 shares of the company's stock, valued at approximately $904,856.36. The trade was a 36.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 20.30% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.